Volume 2: Issue 2
pp71-204
 |
About the CoverThe cover for the issue of Oncoscience features Figure 2 (“SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma”) from Blanco et al. |
News
Editorials
Functional polymorphisms in cancer
https://doi.org/10.18632/oncoscience.129
Divyansh Agarwal, Christos Hatzis, Lajos Pusztai
p 73-74
TIC10/ONC201: a bend in the road to clinical development
https://doi.org/10.18632/oncoscience.133
Yoshimi Endo Greer, Stanley Lipkowitz
p 75-76
BCC or not: Sufu keeps it in check
https://doi.org/10.18632/oncoscience.134
Wen-Chi Yin, Zhu Juan Li, Chi-chung Hui
p 77-78
Fighting Neuroblastomas with NBAT1
https://doi.org/10.18632/oncoscience.126
Gaurav Kumar Pandey, Chandrasekhar Kanduri
p 79-80
Reviews
Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
https://doi.org/10.18632/oncoscience.130
Kimryn W. Rathmell, Fengju Chen, Chad J. Creighton
p 81-90
Abstract | PDF | Full Text | How to Cite
Research Perspectives
Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials
https://doi.org/10.18632/oncoscience.132
Miguel López-Lázaro
p 91-98
PDF | Full Text | How to Cite
MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
https://doi.org/10.18632/oncoscience.135
Mariska Miranda, Esdy Rozali, Kum Kum Khanna, Fares Al-Ejeh
p 99-101
PDF | Full Text | How to Cite
SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma
https://doi.org/10.18632/oncoscience.122
Víctor M. Blanco, Richard Curry, Xiaoyang Qi
p 102-110
PDF | Full Text | How to Cite
Research Papers
Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis – molecular insights from an iTRAQ™ quantitative proteomics study
https://doi.org/10.18632/oncoscience.120
Karthik Narasimhan, Yew Mun Lee, Teck Kwang Lim, Sarah Alexandra Port, Jin-Hua Han, Chien-Shing Chen, Qingsong Lin
p 111-124
Abstract | PDF | Full Text | Supplementary Materials | Supplementary Table | How to Cite
RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.
https://doi.org/10.18632/oncoscience.118
Mariana Petaccia de Macedo, Fernanda Machado de Melo, Júlia da Silva Ribeiro, Celso Abdon Lopes de Mello, Maria Dirlei Ferreira de Souza Begnami, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck da Cunha
p 125-130
Abstract | PDF | Full Text | How to Cite
Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival
https://doi.org/10.18632/oncoscience.119
Esther Martínez-Martínez, Irene Gómez, Paloma Martín, Antonio Sánchez, Laura Román, Eva Tejerina, Félix Bonilla, Antonio García Merino, Antonio García de Herreros, Mariano Provencio, Jose M. García
p 131-141
Abstract | PDF | Full Text | How to Cite
TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells
https://doi.org/10.18632/oncoscience.121
Shin-Jen Lin, Dong-Rong Yang, Nancy Wang, Ming Jiang, Hiroshi Miyamoto, Gonghui Li, Chawnshang Chang
p 142-150
Abstract | PDF | Full Text | Supplementary Materials | How to Cite
Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma
https://doi.org/10.18632/oncoscience.128
Edward Sanders, Svenja Diehl
p 151-186
Abstract | PDF | Full Text | Supplementary Materials | Supplementary Table | How to Cite
Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations
https://doi.org/10.18632/oncoscience.131
Jorge Galvez Silva, Fernando F. Corrales-Medina, Ossama M. Maher, Nizar Tannir, Winston W. Huh, Michael E. Rytting, Vivek Subbiah
p 187-192
Abstract | PDF | Full Text | How to Cite
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
https://doi.org/10.18632/oncoscience.136
Naoko Arichi, Yozo Mitsui, Miho Hiraki, Sigenobu Nakamura, Takeo Hiraoka, Masahiro Sumura, Hiroshi Hirata, Yuichiro Tanaka, Rajvir Dahiya, Hiroaki Yasumoto, Hiroaki Shiina
p 193-204
Abstract | PDF | Full Text | Supplementary Materials | How to Cite